|
KMID : 1144320200520030396
|
|
감염과 화학요법
2020 Volume.52 No. 3 p.396 ~ p.402
|
|
|
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
|
|
Hong Kyung-Soo
Jang Jong-Geol
Hur Ji-An
Lee Jong-Ho
Kim Hong-Nam
Lee Won-Hwa
Ahn June-Hong
|
|
|
Abstract
|
|
|
|
There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.
|
|
|
KEYWORD
|
|
|
Early, Hydroxychloroquine, Coronavirus disease 2019, Eradication
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|